Lou
Showing 1–3 of 3 transcripts.
- The Diary Of A CEO1h 35m
Ex-Pentagon Official: The U.S Isn't Telling The Truth! Top-Secret UFO Encounters Finally Uncovered!
Former Pentagon program head Luis Elizondo asserts that humanity is not alone, citing a classified investigation into Unidentified Aerial Phenomena that revealed objects defying known physics through capabilities like instantaneous acceleration and transmedium travel. Elizondo resigned in 2017 to protest the withholding of critical national security data from top leadership, warning that these non-human technologies pose existential risks to nuclear infrastructure while the intelligence community illegally suppressed findings from Congress and the public. His investigation, which included corroborating sensor data from "Top Gun" pilots and confirmed medical injuries, concludes that these anomalous phenomena are neither adversarial state programs nor mass hallucinations but require an open, data-driven scientific approach to understand their origins and intentions.
- Goldman Sachs6 min
How Investors Are Preparing for Rising Inflation
Recent shifts in trade-weighted dollars and commodity indices signal a transition from deflation to reflation driven by vaccine distribution, unified U.S. fiscal spending, and a flexible Federal Reserve policy. This macroeconomic environment is prompting investors to rotate capital from large-cap technology stocks toward small-cap value equities, real assets, and sectors poised for reopening or supported by renewable energy initiatives. Consequently, market expectations point to robust growth in emerging markets and cyclical opportunities as inflationary pressures reshape asset allocation strategies for 2021.
- Milken Institute1h 2m
Paying for Cures
Colleen Rye, Christiana Bardon, Louis DeGennaro, Joe La Barge, Mark Trusheim, Cynthia Verst, Cindy Virst, Mark Trusseimer, Chris Barden, Joe Medina, Eric Schmidt, Lou, Louis Kombolaini, John McWhorter, Tanisha Carino, Martha Minowski
Discussions on the evolution of curative gene therapies analyze the projected surge of over 500 pipeline candidates and the necessary shift from chronic treatment models to one-time cures that disrupt traditional pricing structures. Industry experts highlight innovative financial mechanisms, including outcomes-based rebates and installment payments, designed to navigate complex regulatory hurdles like Medicaid best price rules and FASB accounting volatility while addressing manufacturing costs. Despite significant challenges in social equity and international reimbursement disparities, the consensus suggests that historical precedents and market-driven competition will ultimately sustain a system capable of integrating these high-cost, durable medical breakthroughs.